Luis G Carvajal‐Carmona

Professor

University of California, Davis
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (41)

Latin America’s population is among the most genetically diverse in the world, shaped by centuries of European colonization, Indigenous American displacement, and forced African slave migration. This complex ancestry, combined with persistent social inequalities, influences cancer risk through both genetic and environmental factors. For example, Indigenous ancestry has been linked to a lower risk of breast cancer, a protective effect further influenced by reproductive patterns and access to healthcare. In this issue, Pinto and colleagues trace the history of the TP53 p.R337H founder variant, a mutation now present in about 1 in 300 people in southern Brazil. Their analysis shows that this variant was introduced during early Portuguese colonization and spread throughout Brazil as the population grew rapidly. This story highlights how historical events continue to shape cancer risk today. Founder mutations, such as TP53 p.R337H, are common across Latin America and often trace to Iberian ancestors. These variants offer unique opportunities for low-cost genetic screening and precision medicine, especially in regions with limited resources. They also serve as natural experiments for studying how genes and the environment interact to influence cancer risk. By understanding and leveraging these genetic legacies, we can enhance cancer prevention and treatment in Latin America, reduce disparities, and gain valuable insights to address global cancer health. See related article by Pinto et al., p. 210

Year:

2026

Breast cancer (BC) is a heterogeneous disease, and triple-negative breast cancer (TNBC) is the most aggressive and immunogenic subtype. A significant proportion of TNBC cases are linked to hereditary cancer syndromes involving pathogenic germline variants, most commonly in BRCA1/2. However, few studies have compared hereditary and sporadic TNBC in admixed populations. In this study, molecular and immunological features were analyzed through the analysis of 62 Colombian TNBC samples (20 hereditary and 42 sporadic cases) by RNA sequencing to identify molecular and immune differences. We used an external validation cohort of 16 TCGA TNBC cases (8 BRCA-mutated and 8 non-mutated) to replicate our findings. Results: We found a set of 921 differentially expressed genes (DEGs) between hereditary and sporadic TNBC. Hereditary tumors were enriched for pathways related to extracellular matrix (ECM) remodeling, structural components, and DNA damage response and exhibited a more immunologically active tumor microenvironment compared to sporadic tumors. LASSO logistic regression identified 23 genes with discriminatory potential, showing that hereditary tumors are characterized by complex immune regulation, inflammatory processes, and activation of key oncogenic pathways. Conclusions: Hereditary TNBC is characterized by molecular and biological functions linked to ECM remodeling and its constituents and an active immune microenvironment. This integrated molecular–immune profile provides insight into the distinct biology of hereditary tumors in admixed populations.

Year:

2025

Genetic studies in Latin America have expanded, but further efforts are needed to understand cancer susceptibility genes beyond BRCA1 and BRCA2 , especially by characterizing the prevalence and spectrum of pathogenic or likely pathogenic variants (PVs) in the region. This study aimed to determine the frequency of hereditary cancer syndromes (HCS) in Colombians with solid tumors and to characterize the spectrum of PVs. Using data from the Colombia’s largest Institutional Hereditary Cancer Program, we included patients aged ≥18 years with solid tumors who met HCS criteria and were offered genetic testing with a 105-cancer gene panel. We calculated the prevalence of PVs and HCS by cancer type (beyond breast) and gene. For patients with breast cancer, we examined genotype-phenotype correlations with molecular subtypes and stratified positivity rates by different genetic testing criteria. Among 769 patients, we identified 216 PVs in 43 genes in 197 patients (26%). Thirty-three PVs were recurrent. Autosomal HCS was found in 21% (160/769) of patients (159 dominant, one recessive), while 5% (37/769) were heterozygous carriers of PVs in autosomal recessive genes. In 42% (321/769) of the cases, only one or more variants of uncertain significance (VUS) were identified, whereas 33% (251/769) had neither PVs nor VUS detected (negative results). HCS prevalence varied by cancer type (11–26%). The triple-negative subtype and bilateral presentation were strong predictors of inherited breast cancer. Our study reveals a significant presence of PVs among high-risk Colombian patients with solid tumors, underscoring the importance of genetic counseling and testing in the region.

Year:

2025

Background: A substantial portion of the genetic predisposition for breast cancer is explained by multiple common genetic variants of relatively small effect. A subset of these variants, which have been identified mostly in individuals of European (EUR) and Asian ancestries, have been combined to construct a polygenic risk score (PRS) to predict breast cancer risk, but the prediction accuracy of existing PRSs in Hispanic/Latinx individuals (H/L) remain relatively low. We assessed the performance of several existing PRS panels with and without addition of H/L-specific variants among self-reported H/L women. Methods: PRS performance was evaluated using multivariable logistic regression and the area under the ROC curve. Results: Both EUR and Asian PRSs performed worse in H/L samples compared with original reports. The best EUR PRS performed better than the best Asian PRS in pooled H/L samples. EUR PRSs had decreased performance with increasing Indigenous American (IA) ancestry, while Asian PRSs had increased performance with increasing IA ancestry. The addition of two H/L SNPs increased performance for all PRSs, most notably in the samples with high IA ancestry, and did not impact the performance of PRSs in individuals with lower IA ancestry. Conclusions: A single PRS that incorporates risk variants relevant to the multiple ancestral components of individuals from Latin America, instead of a set of ancestry-specific panels, could be used in clinical practice. Impact: The results highlight the importance of population-specific discovery and suggest a straightforward approach to integrate ancestry-specific variants into PRSs for clinical application.

Year:

2025

Ancestral estimates 1000Genomes individuals (n=929) not used in reference panel generation. Estimates calculated from 1000Genomes K=10 admixture data, SNPWeights Panel, and the differences between these estimates for each individual.

Year:

2024

Figure S1 shows the Clustering of 1,990 non-admixed reference samples and 2,387 admixed samples(brown) individuals based on the first three principal components. Colors represent the continental ances

Year:

2024

1000Genomes K=10 Admixture Estimates downloaded from ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/supporting/admixture_files/ALL.wgs.phase3_shapeit2_filtered.20141217.maf0.05.10.Q. Super-population designations were added to the partitions by sorting each partition and determining the corresponding designation for each partition.

Year:

2024

PDXnet metadata for samples for which genetic ancestry was estimated and samples were assigned into African (AFR), European (EUR), East Asian (EAS), American (AMR), and South Asian (SAS) continental ancestry.

Year:

2024

PDXnet metadata for samples for which genetic ancestry was estimated and samples were assigned into African (AFR), European (EUR), East Asian (EAS), American (AMR), and South Asian (SAS) continental ancestry.

Year:

2024

1000Genomes K=10 Admixture Estimates downloaded from ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/release/20130502/supporting/admixture_files/ALL.wgs.phase3_shapeit2_filtered.20141217.maf0.05.10.Q. Super-population designations were added to the partitions by sorting each partition and determining the corresponding designation for each partition.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (43)

Lawrence Rubinstein

Statistician

National Cancer Institute

UNITED STATES
View details

Matthew H Bailey

Assistant Professor

Brigham Young University

UNITED STATES
View details

Jose G. Trevino

Virginia Commonwealth University

UNITED STATES
View details

Katherine Chiu

University of California, Davis

UNITED STATES
View details

Christopher A. Haiman

University of Southern California

UNITED STATES
View details

Laura Fejerman

Professor

University of California, Davis

UNITED STATES
View details

Michael A. Davies

-

UNITED STATES
View details

Sherri Davies

Senior Scientist

Washington University in St. Louis

UNITED STATES
View details

FEI CHEN

Assistant Professor

University of Southern California

UNITED STATES
View details

Min Jin Ha

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Lisa McShane

Associate Director, Division of Cancer Treatment & Diagnosis

National Cancer Institute

UNITED STATES
View details

Peter Robinson

Professor for Medical Computer Science

The Jackson Laboratory for Genomic Medicine

UNITED STATES
View details

Jeffrey Chuang

Jackson Laboratory

UNITED STATES
View details

Weang Kee Ho

Professor

Sunway University

MALAYSIA
View details

Bizu Gelaye

Chief, Epidemiology Branch and Senior Investigator

Eunice Kennedy Shriver National Institute of Child Health and Human Development

UNITED STATES
View details

I. King Jordan

Professor

Georgia Institute of Technology

UNITED STATES
View details

Xiaowei Xu

Professor

University of Pennsylvania

UNITED STATES
View details

Shidan Wang

-

UNITED STATES
View details

Junya Fujimoto

Professor and Chair

Hiroshima University Hospital

JAPAN
View details

Alana Welm

Chair

Huntsman Cancer Institute

UNITED STATES
View details

Nicholas Mitsiades

Professor

University of California, Davis

UNITED STATES
View details

Bryan Welm

Associate Professor

Huntsman Cancer Institute

UNITED STATES
View details

Elad Ziv

Professor

University of California

UNITED STATES
View details

Meenhard Herlyn

Professor, Director

The Wistar Institute

UNITED STATES
View details

Xuelin Huang

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Esther John

Professor

Stanford University School of Medicine

UNITED STATES
View details

Shunqiang Li

Associate Professor

Washington University in St. Louis

UNITED STATES
View details

Jing Wang

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ryan C. Fields

University of Rochester

UNITED STATES
View details

Funda Meric-Bernstam

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Robert Mashl

Washington University in St. Louis

UNITED STATES
View details

Chong-xian Pan

Professor

university of california davis medical center

UNITED STATES
View details

Carol Bult

Professor and Knowlton Family Chair

Jackson Laboratory

UNITED STATES
View details

David Conti

Professor

Colorado School of Public Health

UNITED STATES
View details

Salma Kaochar

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details

Li Ding

Associate Professor

Washington University in Saint Louis School of Medicine

UNITED STATES
View details

Michelle Williams

Professor of Epidemiology

Stanford University

UNITED STATES
View details

J. Chuck Harrell

Virginia Commonwealth University

UNITED STATES
View details

Michael Lewis

Baylor College of Medicine

UNITED STATES
View details

Maria Gabriela Raso

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Soner Koc

GlaxoSmithKline Research and Development

UNITED STATES
View details

Guanghua Xiao

-

UNITED STATES
View details

Yang Xie

Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details